Effect of angiotensin converting enzyme inhibitor fosinopril on intravascular blood flow in hypertensive patients
https://doi.org/10.18705/1607-419X-2011-17-3-236-239
Abstract
Background. Organoprotective features should be taken into account when antihypertensive therapy is administered. The infl uence of angiotensin converting enzyme inhibitor (ACEi) on intravascular blood fl ow is unknown. Design and methods. A total of 40 patients with essential hypertension stage I–II (mean age 48,1 ± 14,8 years) were included. All of them got fosinopril therapy for 27 weeks. Examination included: assessment of the common carotid artery diameter, intima-media complex thickness, distensibility coeffi cient, stiffness index, peak systolic velocity of the wall and the central layer of the blood fl ow in the common carotid artery and their relationship — the index of wall blood fl ow slowdown (IWBFS). Results. In addition to a distinct antihypertensive effect, fosinopril induces improvement of elastic properties of the vascular wall, reduces intima-media thickness and increases IWBFS. Conclusion. Fosinopril leads to the increase of IWBFS that may indicate the reduction of turbulent fl ow probability in the common carotid arteries and decreased risk of atherosclerosis.
About the Authors
L. F. Bartosh
Penza Advanced Training Institute for Doctors, Penza
Russian Federation
Russian Federation
L. V. Melnikova
Penza Advanced Training Institute for Doctors, Penza
Russian Federation
Russian Federation
References
1. Гогин Е.Е. Гипертоническая болезнь: основы патогенеза, диагностика и выбор лечения // Cons. medicum. - 2004. - Т. 6, № 5. - С. 324-330.
2.
3. Dahlof B., Sever P.S., Poulter N.R., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // Lancet. - 2005. - Vol. 366, № 9489. - P. 895-906.
4.
5. London G.M., Asmar R.G., O'Rourke M., Safar M.E., on behalf of the REASON Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol // J. Am. Coll. Cardiol. - 2004. - Vol. 43, № 1. - P. 92-9.
6.
7. Бойцов С.А. Изучение патогенеза гипертонической болезни продолжается // Терапевт. арх. - 2006. - № 9. - С. 5-12.
8.
9. Олейников В. Э., Матросова И. Б., Томашевская Ю. А. и др. Влияние ингибитора АПФ спираприла на структурно-функциональные свойства сосудистой стенки при метаболическом синдроме и эссенциальной гипертонии // Рос. кардиол. журн. - 2006. - Т. 58, № 2. - С. 36-41.
10.
11. Asmar R., Topouchian J., Pannier B. et al. Pulse wave velocity as endpoint large scale intervention trial. The Complior study. Scientific, quality control, coordination and investigation committees of the Complior study // J. Hypertens. - 2001. - Vol. 19, № 4. - Р. 813-818.
12.
13. Мельникова Л.В., Бартош Ф.Л., Бартош Л.Ф. Способ диагностики ранних стадий атеросклероза // Патент на изобретение № 2350273. - Бюл. № 9. - 2009. - 11 с.
14.
15. Reneman RS., van Merode T., Hick P. et al. Age-related changes in carotid artery wall properties in men // Ultrasound Med. Biol. - 1986. - Vol. 12, № 6. - Р. 465-471.
16.
17. Kawasaki T., Sasayama S., Yagi S. et al. Nonivasive measurement of the age related changes in stiffness of major branches of the human arteries // Cardiovasc. Res. - 1987. - Vol. 21, № 9. - Р. 678-687.
18.
19. Teicholz L.E., Kreulen T., Herman M.V. Problems of echocardiographic volume determinations: echocardiographic-angiographic correlations in presence or absence of asynergy // Am. J. Cardiol. - 1976. - Vol. 37, № 1. - P. 7-11.
20.
21. Макаров В.А. Физиология человека. - М.: Геотар-Мед, 2001. - 106 с.
22.
23. Щетинин В.В., Берестень Н.Ф. Кардиосовместимая допплерография. - М.: Медицина, 2002. - 240 с.
24.
25. Bonithon-Kopp C., Ducimetiere P., Touboul P.J. et al. Plasma angiotensin-converting enzyme activity and carotid wall thickening // Circulation. - 1994. - Vol. 89, № 3. - P. 952-954.
26.
27. Asmar R., Topouchian J., Pannier B. et al. Pulse wave velocity as endpoint in large-scale intervention trial. Complior study // Hypertension. - 2001. - Vol. 19, № 4. - P. 813-818.
28.
29. Лелюк В.Г., Лелюк С.Э. Возможности дуплексного сканирования в определении объемных показателей мозгового кровотока // Ультразвук. диагност. - 1996. - № 1. - С. 24-32.
30.
31. Сазанов И.И. Гидравлика. Конспект лекций. Учеб. пособ. - М.: ИЦ МГТУ Станкин, 2004. - 292 с.
32.
33. Blann A.D., Lip G.Y. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications // Blood Coagul. Fibrinolysis. - 1998. - Vol. 9, № 4. - P. 297-306.
34.
35. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction // J. Clin. Invest. - 1997. - Vol. 100, № 9. - P. 2153-2157.
36.
37. Лутай М.И. Атеросклероз: современный взгляд на патогенез // Укр. кардиол. жур. - 2003. - № 6. - С. 3-11.
Review
For citations:
Bartosh L.F., Melnikova L.V. Effect of angiotensin converting enzyme inhibitor fosinopril on intravascular blood flow in hypertensive patients. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2011;17(3):236-239. (In Russ.) https://doi.org/10.18705/1607-419X-2011-17-3-236-239
Views:
566
Email this article 